Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Antiepileptics and Blood Dyscrasias: A Cohort Study
Pharmacotherapy 18:1277-1283, Blackburn,S.C.F.,et al, 1998
Chronic Systemic High-Dose Recombinant Interferon Alfa-2a Reduces Exacerbation Rate & MRI Signs in MS
Neurol 44:406-413, Durelli,L.,et al, 1994
A Critical Appraisal of Ticlopidine, A New Antiplat Agent, Effectiveness & Clin Indic for Prophylaxis
Arch Int Med 152:1376-1380, Haynes,R.B.,et al, 1992
Carbamazepine-Induced Antinuclear Antibodies & Systemic Lupus Erythematosus-Like Syndrome
Epilepsia 32:128-129, DeGiorgio,C.M.,et al, 1991